KRAS Gene Mutation
3
Pipeline Programs
4
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
3100%
+ 1 programs with unclassified modality
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Sharp TherapeuticsPA - Pittsburgh
1 program1
PembrolizumabPhase 1Monoclonal Antibody1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Sagimet BiosciencesTVB-2640
Sharp TherapeuticsPembrolizumab
Clinical Trials (2)
Total enrollment: 33 patients across 2 trials
Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas
Start: Sep 2019Est. completion: Dec 202618 patients
Phase 2Active Not Recruiting
Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations
Start: Jun 2018Est. completion: Jun 202415 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
Monoclonal Antibody is the dominant modality (100% of programs)
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.